Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: MRNA expression for 18 chemotherapy-related genes

International Journal of Cancer

Volumn 124, Issue 5, 2009, Pages 1220-1226

  Gustavsson, Bengt ^a   Kaiser, Christopher ^b   Carlsson, Göran ^a   Wettergren, Yvonne ^a   Odin, Elisabeth ^a   Lindskog, Elinor Bexe ^a   Niyikiza, Clet ^c   Doreen, Ma ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

5 FU; ERCC1; Irinotecan; Oxaliplatin; TP; TS

Indexed keywords

CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; CYCLOOXYGENASE 2; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIHYDROFOLATE REDUCTASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MESSENGER RNA; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; OXALIPLATIN; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEIN KINASE C BETA; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC ANTIMETABOLITE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GENE; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE;

EID: 58749116650     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23852     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74 - 108.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041 - 7. Erratum 355(9212): 1372.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000;343:905 - 14.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938 - 47.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335 - 42.
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337 - 45.
7. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997;80: 1179 - 87.
8. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protractedinfusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15: 3223 - 9.
9. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721 - 8.
10. Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 2006;16:809 - 16.
11. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao- Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322 - 7.
12. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298 - 304.
13. Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006;17:35 - 42.
14. Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Anticancer Res 2007;27:851 - 6.
15. Bendardaf R, Elzagheid A, Lamlum H, Algars A, Korkeila E, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S. Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases. Scand J Gastroenterol 2007;42: 471 - 6.
16. Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815 - 19.
17. Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP, Larsson L, Gustavsson B. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003;9(16 Part 1):6012 - 19.
18. Lassmann S, Hennig M, Rosenberg R, Nahrig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Hofler H, Werner M. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006;21:238 - 47.
19. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786 - 91.
20. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 2004;54:531 - 6.
21. Van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, van Gennip AH. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997;33: 2258 - 64.
22. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998 - 1002.
23. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110 - 17.
24. Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T, Muto T. Expression of plateletderived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 2000;88:42 - 9.
25. Kitadai Y, Onogawa S, Kuwai T, Matsumura S, Hamada H, Ito M, Tanaka S, Yoshihara M, Chayama K. Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma. Oncol Rep 2004;11:315 - 19.
26. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV. High basal level gene expression of thymidine phosphorylase (plateletderived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4: 2371 - 6.
27. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006;29:408 - 17.
28. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:4069 - 77.
29. Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31 - 8.
30. Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics 1982;38:1011 - 16.
31. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972;34:187 - 220.
32. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006;70:366 - 77.
33. Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2007;120:694 - 701.
34. Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD, Danenberg PV. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004;10:433 - 9.
35. Cheng Q, Wu B, Kager L, Panetta JC, Zheng J, Pui CH, Relling MV, Evans WE. A substrate specific functional polymorphism of human γglutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004;14:557 - 67.
36. Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH. Identification of the angiogenic endothelial - cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006;107:4954 - 60.
37. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV. 5-Fluorouracil- related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 2006;119:522 - 6.
38. Lenz HJ. Pharmacogenomics and colorectal cancer. Adv Exp Med Biol 2006;587:211 - 31.
39. Meyerhardt J, Stuart K, Fuchs C, Zhu A, Earle C, Bhargava P, Blaszkowsky L, Enzinger P, Mayer R, Battu S, Lawrence C, Ryan D. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncol 2007;18: 1185 - 9.
40. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313 - 27.